28th Nov 2013 07:00
News Release
28 November 2013
Consort Medical plc
Major long-term commercial supply contract award - dry powder inhaler
Consort Medical plc ("Consort" or "The Group") (LSE: CSRT), is delighted to announce it has entered into a commercial supply agreement relating to its development programme DEV610.
Bespak has signed a multi-year contract, with an initial exclusivity period, to serve as the contract manufacturer of a customer's proprietary dry powder inhaler (DPI). The customer is a global pharma company whose details remain confidential at this time.
For Bespak this is a significant opportunity, which requires the construction of a further dedicated building at the King's Lynn site to accommodate the additional moulding and assembly capacity to produce the contracted volumes. Revenues from the contract will be dependent on sales following regulatory approval and launch of any products utilizing the device. The programme is referenced on Consort's development pipeline as DEV610, and its initial launch is expected in 2015.
Jonathan Glenn, Consort Medical Chief Executive commented: "We are delighted to have secured this major contract, which further leverages our operational and regulatory expertise in the production of high volume, premium quality drug delivery devices. This represents a further execution of our strategy for organic growth"
Consort will announce its Interim results for on Wednesday 4 December 2013.
-Ends-
Enquiries:
ConsortJonathan Glenn - Chief Executive Richard Cotton - Finance Director | Tel: +44 1442 867920 |
Brunswick Group Jon Coles / Pip Green / Anna Carruth | Tel: +44 20 7404 5959
|
Consort Medical plc is an international medical devices company, focused on developing and manufacturing disposable medical devices for drug delivery. The principal business of the Company is the management of Bespak, a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.
The Group has facilities in King's Lynn, Cambridge, Nelson, Milton Keynes and Hemel Hempstead in the UK. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT). The Group's website address is www.consortmedical.com.
Related Shares:
CSRT.L